Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Mendiola, Marta
dc.contributor.author Martínez-Marín, Virginia
dc.contributor.author Herranz, Jesús
dc.contributor.author Heredia, Victoria
dc.contributor.author Yébenes, Laura
dc.contributor.author Zamora, Pilar
dc.contributor.author Castelo, Beatriz
dc.contributor.author Pinto, Álvaro
dc.contributor.author Miguel, María
dc.contributor.author Díaz, Esther
dc.contributor.author Gámez, Angelo
dc.contributor.author Fresno, Juan Ángel
dc.contributor.author Ramírez de Molina, Ana
dc.contributor.author Hardisson, David
dc.contributor.author Espinosa, Enrique
dc.contributor.author Redondo, Andrés
dc.contributor.other UAM. Departamento de Anatomía Patológica es_ES
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) es_ES
dc.date.accessioned 2017-04-07T17:10:47Z
dc.date.available 2017-04-07T17:10:47Z
dc.date.issued 2016-03-16
dc.identifier.citation Oncotarget 7.17 (2016): 24217-24227 en_US
dc.identifier.issn 1949-2553 es_ES
dc.identifier.uri http://hdl.handle.net/10486/677937
dc.description.abstract Bevacizumab plus weekly paclitaxel improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC), but its use has been questioned due to the absence of a predictive biomarker, lack of benefit in overall survival (OS) and increased toxicity. We examined the baseline tumor angiogenic-related gene expression of 60 patients with mBC with the aim of finding a signature that predicts benefit from this drug. Multivariate analysis by Lasso-penalized Cox regression generated two predictive models: one, named G-model, including 11 genes, and the other one, named GCmodel, including 13 genes plus 5 clinical covariates. Both models identified patients with improved PFS (HR (Hazard Ratio) 2.57 and 4.04, respectively) and OS (HR 3.29 and 3.43, respectively). The G-model distinguished low and high risk patients in the first 6 months, whereas the GC-model maintained significance over time en_US
dc.description.sponsorship This work was supported by a grant from the Independent Clinical Research Program (EC10-342), Independent Clinical Research Program (EC10-342), ISCIII (Instituto de Salud Carlos III), Spanish Ministry of Health, and funded also from Roche Farma S.A.U. en_US
dc.format.extent 11 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher Impact Journals LLC en_US
dc.relation.ispartof Oncotarget en_US
dc.subject.other Metastatic breast carcinoma en_US
dc.subject.other Bevacizumab and weekly paclitaxel en_US
dc.subject.other Predictive en_US
dc.subject.other Angiogenesis en_US
dc.subject.other Gene expression en_US
dc.title Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.identifier.publicationfirstpage 24217 es_ES
dc.identifier.publicationissue 17 es_ES
dc.identifier.publicationlastpage 24227 es_ES
dc.identifier.publicationvolume 7 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.accessRights openAccess en
dc.authorUAM Hardisson Hernáez, David Alonso (260363)
dc.authorUAM Herranz Barrera, Jesús (260466)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record